Apolipoprotein E ?4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease
Authors:
- 1 November 1998
- journal article
- research article
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 13 (11) , 767-774
Abstract
To better define the influence of apolipoprotein E (ApoE) ϵ4 genotype on the cognitive and biochemical features of Alzheimer's disease (AD), cross-sectional analysis of global cognitive measures and cerebrospinal fluid studies gathered on AD subjects at a tertiary care facility between 1986 and 1997 was carried out. The 112 AD patients examined included 62 women and 50 men with a mean (SD) age of 64·2 (9·2) years. Patient demographics, illness onset age and duration, education level and global cognitive measures were recorded systematically. Genetic analysis for ApoE allele type and biochemical characterization of CSF, including total tau concentration, was performed. Descriptive statistics of demographics, cognitive and CSF measures were performed by chi-square, ANOVA and Tukey's tests. Overrepresentation of the ϵ4 allele was found, with 45·5% of AD patients heterozygous and 20·5% homozygous for ApoE ϵ4. Overall, ApoE ϵ4 status had no effect on mean onset age of AD (F=1·56; p=0·214), but an earlier mean onset age of AD (F=4·10; p=0·02) was seen in the late-onset subjects. No differences were found with regard to ApoE ϵ4 status and measures of disease, duration of illness or global cognitive performance. Although CSF tau was elevated in our sample (575·4±290·3 pg/ml), ApoE ϵ4 status did not influence total CSF tau or neurotransmitter metabolite levels. ApoE ϵ4 genotype had no impact on a variety of illness severity, cognitive and CSF examinations in the largest cross-sectional analysis of AD subjects yet reported. Copyright © 1998 John Wiley & Sons, Ltd.Keywords
This publication has 57 references indexed in Scilit:
- Apolipoprotein E Genotyping and Cerebrospinal Fluid Tau Protein: Implications for the Clinical Diagnosis of Alzheimer’s DiseaseGerontology, 1997
- Neurochemical Differences in the CSF between Binswanger's and Alzheimer's DiseaseDementia and Geriatric Cognitive Disorders, 1996
- Apolipoprotein-E ε-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's diseaseNeuroscience Letters, 1994
- Association of the apolipoprotein E ϵ4 allele with clinical subtypes of autopsy‐confirmed Alzheimer's diseaseAmerican Journal of Medical Genetics, 1994
- Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.Proceedings of the National Academy of Sciences, 1993
- Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactionsNeuron, 1993
- Apolipoprotein E: Binding to Soluble Alzheimer′s β-AmyloidBiochemical and Biophysical Research Communications, 1993
- Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's diseaseNeurobiology of Aging, 1992
- Apolipoprotein E phenotyping from serum by Western blottingElectrophoresis, 1986
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982